See more : WMCH Global Investment Limited (8208.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Recursion Pharmaceuticals, Inc. (RXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Recursion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Metrospaces, Inc. (MSPC) Income Statement Analysis – Financial Results
- Yancoal Australia Ltd (YAL.AX) Income Statement Analysis – Financial Results
- Sharika Enterprises Limited (SHARIKA.BO) Income Statement Analysis – Financial Results
- Fortress REIT Limited (FFA.JO) Income Statement Analysis – Financial Results
- Huneed Technologies (005870.KS) Income Statement Analysis – Financial Results
Recursion Pharmaceuticals, Inc. (RXRX)
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 44.58M | 39.68M | 10.00M | 3.41M | 1.71M |
| Cost of Revenue | 42.59M | 48.28M | 9.10M | 63.32M | 45.81M |
| Gross Profit | 1.99M | -8.59M | 896.00K | -59.91M | -44.10M |
| Gross Profit Ratio | 4.46% | -21.66% | 8.96% | -1,755.23% | -2,577.32% |
| Research & Development | 241.23M | 155.70M | 135.27M | 63.32M | 45.81M |
| General & Administrative | 110.82M | 81.60M | 57.68M | 25.26M | 18.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 110.82M | 81.60M | 57.68M | 25.26M | 18.95M |
| Other Expenses | 0.00 | -162.00K | -178.00K | -549.00K | -608.00K |
| Operating Expenses | 352.05M | 237.13M | 192.78M | 88.03M | 64.15M |
| Cost & Expenses | 394.64M | 285.41M | 192.78M | 88.03M | 64.15M |
| Interest Income | 19.12M | 6.25M | 73.00K | 336.00K | 1.74M |
| Interest Expense | 97.00K | 55.00K | 2.95M | 1.36M | 635.00K |
| Depreciation & Amortization | 24.40M | 19.49M | 9.10M | 4.44M | 3.54M |
| EBITDA | -299.57M | -227.67M | -174.42M | -81.70M | -58.34M |
| EBITDA Ratio | -672.05% | -619.26% | -1,827.75% | -2,353.38% | -3,401.52% |
| Operating Income | -350.06M | -245.73M | -182.78M | -84.62M | -62.44M |
| Operating Income Ratio | -785.33% | -619.26% | -1,827.75% | -2,479.20% | -3,649.39% |
| Total Other Income/Expenses | 17.93M | 6.25M | -3.70M | -2.39M | 562.00K |
| Income Before Tax | -332.13M | -239.48M | -186.48M | -87.01M | -61.88M |
| Income Before Tax Ratio | -745.10% | -603.50% | -1,864.79% | -2,549.25% | -3,616.54% |
| Income Tax Expense | -4.06M | -55.00K | -8.41M | 876.00K | 646.00K |
| Net Income | -328.07M | -239.42M | -178.07M | -87.88M | -62.53M |
| Net Income Ratio | -735.99% | -603.36% | -1,780.74% | -2,574.92% | -3,654.30% |
| EPS | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| EPS Diluted | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Weighted Avg Shares Out | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
| Weighted Avg Shares Out (Dil) | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
Is Recursion Pharmaceuticals a Warren Buffett Stock?
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Is Recursion Pharmaceuticals Stock a Buy?
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Source: https://incomestatements.info
Category: Stock Reports